Skip to main content
. 2021 Feb 25;36(1):693–706. doi: 10.1080/14756366.2021.1890726

Table 7.

Pyridines CDK9 inhibitors published by AstraZeneca.

Compounds* CDK9 (IC50, nM) ATP conc. At Km CDK9 (IC50, nM) high ATP conc. Phospho-RNAPolyII Ser2 (IC50, nM) Caspase activity MV4-11 (IC50, nM)
42 <3 <3 <7 13
43 <3 <4 11 15
44 <3 <3 10 15
45 <3 <3 7 10
46 <3 9 38 36

CDK: cyclin-dependent kinase; IC50: half maximal inhibitory concentration; Phospho-RNAPolyII: phosphorylated RNA polymerase II. *From the corresponding structures in Figure 6.